[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Baumann CR, Schuknecht B, Lo Russo G, Cossu M, Citterio A, Andermann F, Siegel AM: Seizure outcome after resection of cavernous malformations is better when surrounding hemosiderin-stained brain also is removed. Epilepsia; 2006 Mar;47(3):563-6
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Considering the epileptogenic effect of cavernoma-surrounding hemosiderin, assumptions are made that resection only of the cavernoma itself may not be sufficient as treatment of symptomatic epilepsy in patients with cavernous malformations.
  • The purpose of this study was to test the hypothesis whether seizure outcome after removal of cavernous malformations may be related to the extent of resection of surrounding hemosiderin-stained brain tissue.
  • METHODS: In this retrospective study, 31 consecutive patients with pharmacotherapy-refractory epilepsy due to a cavernous malformation were included.
  • RESULTS: Three years after resection of cavernomas, patients in whom hemosiderin-stained brain tissue had been removed completely had a better chance for a favorable long-term seizure outcome compared with those with detectable postoperative hemosiderin (p=0.037).
  • CONCLUSIONS: Our study suggests that complete removal of cavernoma-surrounding hemosiderin-stained brain tissue may improve epileptic outcome after resection of cavernous malformations.
  • [MeSH-major] Brain / metabolism. Brain / surgery. Cavernous Sinus / abnormalities. Cavernous Sinus / surgery. Epilepsy / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Hemosiderin / metabolism. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Anticonvulsants / therapeutic use. Coloring Agents. Drug Resistance. Female. Follow-Up Studies. Humans. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Period. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529622.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Coloring Agents; 9011-92-1 / Hemosiderin
  •  go-up   go-down


2. Mateo-Sierra O, Gutiérrez FA, Fernández-Carballal C, Pinilla D, Mosqueira B, Iza B, Carrillo R: [Akinetic mutism related to hydrocephalus and cerebellar surgery treated with bromocriptine and ephedrine. A pathophysiological review]. Neurocirugia (Astur); 2005 Apr;16(2):134-41; discussion 141
Hazardous Substances Data Bank. (L)-EPHEDRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However successful treatment of this second type of AM has been achieved with bromocriptine.
  • We present a patient who developed AM after a posterior fossa surgery complicated by ventriculitis and multiple hydrocephalic events.
  • Damage to dentate nucleus or its efferents (mainly of glutamate) should promote AM of cerebellar origin, while damage to paraventricular monoaminergic pathways could explain AM related to repeated shunt failures which has successful response to bromocriptine treatment.
  • [MeSH-major] Akinetic Mutism / drug therapy. Akinetic Mutism / etiology. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Bromocriptine / therapeutic use. Central Nervous System Stimulants / therapeutic use. Cerebellum / pathology. Cerebellum / surgery. Dopamine Agonists / therapeutic use. Ephedrine / therapeutic use. Hemangioma, Cavernous, Central Nervous System / pathology. Hemangioma, Cavernous, Central Nervous System / surgery. Hydrocephalus / complications. Postoperative Complications
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neurosurgical Procedures / methods. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hydrocephalus.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915303.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Dopamine Agonists; 3A64E3G5ZO / Bromocriptine; GN83C131XS / Ephedrine
  • [Number-of-references] 28
  •  go-up   go-down


3. Stockton RA, Shenkar R, Awad IA, Ginsberg MH: Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med; 2010 Apr 12;207(4):881-96
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives. 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology. 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / therapeutic use. Animal Structures / blood supply. Animal Structures / metabolism. Animals. Brain Edema / drug therapy. Brain Edema / genetics. Brain Edema / pathology. Edema, Cardiac / drug therapy. Edema, Cardiac / genetics. Edema, Cardiac / pathology. Endothelial Cells / drug effects. Endothelial Cells / metabolism. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Hemangioma, Cavernous, Central Nervous System / drug therapy. Hemangioma, Cavernous, Central Nervous System / metabolism. Hemangioma, Cavernous, Central Nervous System / pathology. Humans. Mice. Mice, Inbred C57BL. Mice, Mutant Strains. Microtubule-Associated Proteins / genetics. Microtubule-Associated Proteins / metabolism. Mutation / physiology. Myosin Light Chains / metabolism. Phosphorylation / drug effects. Phosphorylation / genetics. Protein Binding / physiology. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Pulmonary Edema / genetics. Pulmonary Edema / pathology. RNA, Small Interfering / genetics. rho-Associated Kinases / antagonists & inhibitors. rho-Associated Kinases / metabolism

  • Genetic Alliance. consumer health - Vascular Malformations.
  • Genetics Home Reference. consumer health - cerebral cavernous malformation.
  • Genetics Home Reference. consumer health - CCM2 gene.
  • Genetics Home Reference. consumer health - KRIT1 gene.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Biotechnol. 2007;7:40 [17623073.001]
  • [Cites] Methods Enzymol. 2007;428:297-312 [17875425.001]
  • [Cites] Curr Opin Cell Biol. 2008 Apr;20(2):242-8 [18282695.001]
  • [Cites] FASEB J. 2008 Jun;22(6):1829-38 [18245172.001]
  • [Cites] Hum Mol Genet. 2008 Aug 15;17(16):2424-32 [18469344.001]
  • [Cites] J Physiol. 2008 Nov 1;586(Pt 21):5047-61 [18787034.001]
  • [Cites] Neurosurgery. 2008 Oct;63(4):782-9; discussion 789 [18981890.001]
  • [Cites] Neurosurgery. 2008 Oct;63(4):790-7; discussion 797-8 [18981891.001]
  • [Cites] Stroke. 2008 Dec;39(12):3222-30 [18974380.001]
  • [Cites] Nat Med. 2009 Feb;15(2):169-76 [19151727.001]
  • [Cites] Nat Med. 2009 Feb;15(2):177-84 [19151728.001]
  • [Cites] J Immunol. 2009 Feb 15;182(4):2385-94 [19201893.001]
  • [Cites] Hum Mol Genet. 2009 Mar 1;18(5):919-30 [19088123.001]
  • [Cites] Hum Mol Genet. 2009 Mar 1;18(5):911-8 [19088124.001]
  • [Cites] Dis Model Mech. 2009 Mar-Apr;2(3-4):168-77 [19259391.001]
  • [Cites] Stroke. 2009 May;40(5):1659-65 [19286587.001]
  • [Cites] J Biol Chem. 2009 May 15;284(20):13301-5 [19318350.001]
  • [Cites] Brain Res Bull. 2010 Jan 15;81(1):191-5 [19723568.001]
  • [Cites] Hum Mol Genet. 1999 Nov;8(12):2325-33 [10545614.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 7):1343-55 [11257000.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Aug;71(2):188-92 [11459890.001]
  • [Cites] J Appl Physiol (1985). 2001 Oct;91(4):1487-500 [11568129.001]
  • [Cites] J Cell Sci. 2002 May 1;115(Pt 9):1837-46 [11956315.001]
  • [Cites] J Anat. 2002 Jun;200(6):549-60 [12162723.001]
  • [Cites] Nat Cell Biol. 2003 Dec;5(12):1104-10 [14634666.001]
  • [Cites] Am J Hum Genet. 2003 Dec;73(6):1459-64 [14624391.001]
  • [Cites] Development. 2004 Mar;131(6):1437-48 [14993192.001]
  • [Cites] Neurosurgery. 2004 Jul;55(1):1-16; discussion 16-7 [15214969.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1509-18 [15509522.001]
  • [Cites] Oncogene. 1997 Aug 28;15(9):1043-9 [9285558.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):46621-30 [15333633.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1950-5 [15374886.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Apr;288(4):L749-60 [15591411.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11675-82 [15661741.001]
  • [Cites] Surg Neurol. 2005 Apr;63(4):317-8 [15808708.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1158-62 [15891176.001]
  • [Cites] Hum Mol Genet. 2005 Sep 1;14(17):2521-31 [16037064.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1767-75 [16002741.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 Sep;5(5):391-6 [16131422.001]
  • [Cites] FEBS Lett. 2005 Sep 12;579(22):4966-72 [16115630.001]
  • [Cites] Atherosclerosis. 2005 Nov;183(1):1-16 [15982657.001]
  • [Cites] Stroke. 2006 Feb;37(2):518-23 [16373645.001]
  • [Cites] Mamm Genome. 2006 Feb;17(2):119-28 [16465592.001]
  • [Cites] Circ Res. 2006 Feb 17;98(3):322-34 [16484628.001]
  • [Cites] Microcirculation. 2006 Apr-May;13(3):237-47 [16627366.001]
  • [Cites] Gene Expr Patterns. 2006 Jun;6(5):495-503 [16455310.001]
  • [Cites] Development. 2006 Aug;133(16):3139-46 [16873582.001]
  • [Cites] Nat Cell Biol. 2006 Nov;8(11):1223-34 [17060906.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):8065-71 [17114480.001]
  • [Cites] Am J Hum Genet. 2007 Jan;80(1):69-75 [17160895.001]
  • [Cites] BMC Dev Biol. 2007;7:2 [17214902.001]
  • [Cites] Neurosurgery. 2006 Dec;59(6):1278-84; discussion 1284-5 [17277691.001]
  • [Cites] Neurosurgery. 2007 Feb;60(2):353-9; discussion 359 [17290187.001]
  • [Cites] Prog Neurol Surg. 2007;20:231-4 [17317991.001]
  • [Cites] J Cell Biol. 2007 Oct 22;179(2):247-54 [17954608.001]
  • [Cites] Neurogenetics. 2007 Nov;8(4):249-56 [17657516.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4343-55 [17900104.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):1023-6 [17977276.001]
  • [Cites] Neurosurg Rev. 2008 Jan;31(1):11-7; discussion 17-8 [17957396.001]
  • [Cites] Am J Pathol. 2008 Feb;172(2):521-33 [18187566.001]
  • [Cites] J Investig Med. 2008 Apr;56(4):720-5 [18382268.001]
  • [Cites] Am J Respir Crit Care Med. 2007 May 15;175(10):1027-35 [17322107.001]
  • [Cites] Mol Biol Cell. 2007 Jun;18(6):2346-55 [17429073.001]
  • [Cites] Brain Res. 2007 Jun 18;1154:215-24 [17482584.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2007 Jul 5;144B(5):691-5 [17440989.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Jul;293(1):L60-8 [17435079.001]
  • (PMID = 20308363.001).
  • [ISSN] 1540-9538
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine; 0 / CCM2 protein, human; 0 / Carrier Proteins; 0 / KRIT1 protein, human; 0 / Krit1 protein, mouse; 0 / Microfilament Proteins; 0 / Microtubule-Associated Proteins; 0 / Myosin Light Chains; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / osmosensing scaffold for MEKK3 protein, mouse; 103745-39-7 / fasudil; 124671-05-2 / RHOA protein, human; 84477-87-2 / 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; EC 2.7.11.1 / rho-Associated Kinases; EC 3.6.5.2 / rhoA GTP-Binding Protein
  • [Other-IDs] NLM/ PMC2856024
  •  go-up   go-down


Advertisement
4. Leussink VI, Flachenecker P, Brechtelsbauer D, Bendszus M, Sliwka U, Gold R, Becker G: Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand; 2003 Jan;107(1):54-61
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches.
  • OBJECTIVE: Superficial siderosis of the central nervous system (CNS) is a rare chronic progressive disorder caused by chronic subarachnoid hemorrhage.
  • We present four patients with superficial siderosis of the CNS to describe the characteristic symptoms, and to discuss the pathogenetic heterogeneity and possible new therapeutic approaches.
  • In two patients surgical treatment of ependymoma or cerebral cavernomas were the underlying diseases.
  • For the first time, we present one patient with vasculitis of the central nervous system associated with systemic hemochromatosis in superficial siderosis.
  • Therapeutic approaches included exstirpation of cavernomas as the source of chronic bleeding in one patient, immunosuppressive therapy and venupunctures in the patient with vasculitis and hemochromatosis, and symptomatic treatment with chelating agents and antioxidants.
  • CONCLUSIONS: Our cases underline the pathogenetic heterogeneity of superficial siderosis and favor the early diagnosis for prompt initiation of therapy.
  • Besides treatment of the underlying condition, antioxidants and radical scavengers may be effective in halting the progression of the disease.
  • [MeSH-minor] Adult. Aged. Antioxidants / therapeutic use. Brain Neoplasms / surgery. Cerebral Angiography. Ependymoma / surgery. Female. Free Radical Scavengers / therapeutic use. Hemangioma, Cavernous / surgery. Humans. Male. Middle Aged. Neurologic Examination / drug effects. Postoperative Complications / diagnosis. Postoperative Complications / etiology. Prognosis

  • Genetic Alliance. consumer health - Siderosis.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12542514.001).
  • [ISSN] 0001-6314
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Free Radical Scavengers
  •  go-up   go-down


5. Petridis AK, Hempelmann RG, Hugo HH, Eichmann T, Mehdorn HM: Metastatic low-grade inflammatory myofibroblastic tumor (IMT) in the central nervous system of a 29-year-old male patient. Clin Neuropathol; 2004 Jul-Aug;23(4):158-66
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic low-grade inflammatory myofibroblastic tumor (IMT) in the central nervous system of a 29-year-old male patient.
  • Computer tomography identified a bleeding in the left frontal lobe.
  • In the further clinical history the patient developed a large spinal cord metastasis of the thoracic spine.
  • The current therapy of these tumors consists of complete tumor resection and further clinical controls.
  • There is no proven role of chemotherapy and radiation therapy.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Fibrosarcoma / secondary. Lung Neoplasms / pathology. Neoplasms, Muscle Tissue / secondary
  • [MeSH-minor] Adult. Diagnosis, Differential. Hemangioma, Cavernous, Central Nervous System / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15328880.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Melot A, Laquerrière A, Hanzen S, Fréger P, Proust F: [Radiation-induced cavernoma of the central nervous system]. Neurochirurgie; 2007 Dec;53(6):495-500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiation-induced cavernoma of the central nervous system].
  • [Transliterated title] Cavernome radio-induit du système nerveux central. A propos d'un cas.
  • Central nervous system radiation-induced cavernoma (RIC) is a rare entity.
  • This case illustrates the following features: mean age of 11.7 years at time of radiation and mean latency period of nine years for these RIC, which are often numerous (38%), and located in the field of the craniospinal radiation therapy.
  • This nosological entity belongs to the spectrum of radiation-induced lesions, and requires a long-term MRI follow up in patients who underwent cranial radiation therapy.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Hemangioma, Cavernous, Central Nervous System / etiology. Neoplasms, Radiation-Induced / pathology
  • [MeSH-minor] Adolescent. Drug Resistance, Neoplasm. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061632.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Mauguière F: [Epileptogenicity and evaluation of epileptic risk]. Neurochirurgie; 2007 Jun;53(2-3 Pt 2):156-62
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As for all epileptogenic lesions, many questions arise: Is the pathologic tissue or the perilesional cortex responsible for the epileptic symptoms?
  • Can the epilepsy become drug-resistant?
  • Can surgical treatment cure the epilepsy?
  • When surgery is indicated, should lesionectomy alone or lesionectomy plus perilesional tissue resection be performed?
  • The iron and the hemosiderin deposits induce metabolic perturbations and tissue reorganization (gliosis and sclerosis) around the cavernoma.
  • Epileptic discharges have been recorded in the perilesional tissue in only one study of the literature.
  • Drug therapy can usually control the seizures, but it appears that surgery is more effective when the epilepsy is recent and the seizures are not too frequent.
  • In case of drug-resistant epilepsy, the same function-targeted surgical strategy may be used as for the management of any severe epilepsy.
  • [MeSH-major] Central Nervous System Neoplasms / complications. Epilepsy / etiology. Hemangioma, Cavernous, Central Nervous System / complications
  • [MeSH-minor] Animals. Brain Chemistry / physiology. Cerebral Cortex / pathology. Drug Resistance. Electroencephalography. Humans. Magnetoencephalography. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507046.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 43
  •  go-up   go-down


8. Chazal J, Khalil T, Sakka L: [Therapeutic indications for central nervous system cavernomas]. Neurochirurgie; 2007 Jun;53(2-3 Pt 2):251-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic indications for central nervous system cavernomas].
  • [Transliterated title] Indications thérapeutiques des cavernomes du système nerveux central.
  • We describe the therapeutic indications for central nervous system cavernomas based on three criteria:.
  • Treatment of a symptomatic forms remains debatable, opinion being divided between therapeutic abstention and surgery (in case of cavernomas close to the pia matter or the ependyma).
  • Scientific data strongly support surgical indication for lesions presenting with epilepsy specially when drug-resistant;.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Hemangioma, Cavernous, Central Nervous System / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498755.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 21
  •  go-up   go-down


9. Yadav N, Prabhakar H, Singh GP, Bindra A, Ali Z, Bithal PK: Acute hemodynamic instability during alcohol ablation of symptomatic vertebral hemangioma: a prospective study. J Clin Neurosci; 2010 Jun;17(6):810-1
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute hemodynamic instability during alcohol ablation of symptomatic vertebral hemangioma: a prospective study.
  • Symptomatic vertebral hemangiomas (SVH) are difficult to treat and many therapeutic options, including surgery, radiotherapy, arterial embolization, and injection of methyl-methacrylate into hemagiomatous vertebrae have been reported.
  • Alcohol ablation of vertebral hemangiomas is an effective management option; however, a literature search did not reveal any reports of anesthetic complications or hemodynamic instability during and report a series of four males and seven females and report hemodynamic variations observed at the time of injection of absolute ethanol under general anesthetic, for the treatment of SVH.
  • All patients developed transient hypotension and bradycardia at the time of alcohol injection (8-10 mL of absolute alcohol).
  • [MeSH-major] Bradycardia / chemically induced. Central Nervous System Depressants / adverse effects. Ethanol / adverse effects. Hemodynamics / drug effects. Hypertension / chemically induced
  • [MeSH-minor] Adolescent. Adult. Child. Female. Hemangioma / drug therapy. Humans. Lumbar Vertebrae. Male. Prospective Studies. Spinal Neoplasms / drug therapy. Young Adult

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20400319.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 3K9958V90M / Ethanol
  •  go-up   go-down


10. Cauley KA, Andrews T, Gonyea JV, Filippi CG: Magnetic resonance diffusion tensor imaging and tractography of intracranial cavernous malformations: preliminary observations and characterization of the hemosiderin rim. J Neurosurg; 2010 Apr;112(4):814-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study was to investigate the diffusion tensor (DT) properties of CMs, the hemosiderin rim, and normal-appearing adjacent white matter.
  • METHODS: Eighteen cavernous malformations were characterized using standard MR imaging sequences as well as 6-direction DT imaging with single-shot echo planar-gradient echo imaging at 3 tesla.
  • RESULTS: Diffusion tensor imaging demonstrated that CMs have a characteristic signature on DT imaging, with low fractional anisotropy (FA) and high mean diffusivity centrally within the lesion.
  • The hemosiderin rim had a high FA value relative to the central lesion or adjacent white matter.
  • CONCLUSIONS: The hemosiderin rim of CMs was intimately associated with white matter tracts that were deviated by the central lesion.
  • [MeSH-major] Diffusion Tensor Imaging. Echo-Planar Imaging. Hemangioma, Cavernous, Central Nervous System / metabolism. Hemangioma, Cavernous, Central Nervous System / pathology. Hemosiderin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367384.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9011-92-1 / Hemosiderin
  •  go-up   go-down


11. Abejón D, del Saz JM, Ley L, Sánchez MR, del Pozo C: [Spinal granuloma in a patient receiving a spinal infusion of morphine and clonidine]. Rev Esp Anestesiol Reanim; 2009 Jun-Jul;56(6):380-4
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a man with central neuropathic pain after removal of a tumor.
  • [MeSH-major] Analgesia, Epidural / instrumentation. Analgesics, Opioid / therapeutic use. Back Pain / etiology. Catheterization / adverse effects. Clonidine / therapeutic use. Granuloma, Foreign-Body / etiology. Infusion Pumps, Implantable / adverse effects. Morphine / therapeutic use. Muscle Relaxants, Central / therapeutic use. Neuralgia / etiology. Postoperative Complications / etiology. Spinal Cord Compression / etiology
  • [MeSH-minor] Drug Therapy, Combination. Emergencies. Hemangioma, Cavernous, Central Nervous System / surgery. Humans. Infusions, Parenteral / instrumentation. Laminectomy. Male. Middle Aged. Spinal Cord Diseases / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Back Pain.
  • Hazardous Substances Data Bank. CLONIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19725346.001).
  • [ISSN] 0034-9356
  • [Journal-full-title] Revista española de anestesiología y reanimación
  • [ISO-abbreviation] Rev Esp Anestesiol Reanim
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Muscle Relaxants, Central; 76I7G6D29C / Morphine; MN3L5RMN02 / Clonidine
  •  go-up   go-down


12. Nakazaki K, Titoku S, Ota S, Sato M, Kobanawa S, Tutida K, Tanaka Y, Goto K, Ota T: [Lacunar infarction in brain tumor patients: chronic stage complication after radiation therapy]. No Shinkei Geka; 2007 Oct;35(10):1019-23
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lacunar infarction in brain tumor patients: chronic stage complication after radiation therapy].
  • The authors reported two relatively young adults with lacunar infarction that took place many years after radiation therapy.
  • This patient had received radiation therapy and chemotherapy for a right basal ganglia germinoma when he was 24 years old.
  • The patient had received radiation therapy for a suprasellar tumor when she was 11 years old.
  • Review of the literature was made and the possibility of radiation therapy as a causative factor of the lacunar infarction in relatively young adults was discussed.
  • [MeSH-major] Brain Infarction / etiology. Brain Neoplasms / radiotherapy. Germinoma / radiotherapy. Hemangioma, Cavernous, Central Nervous System / radiotherapy. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Age Factors. Female. Humans. Magnetic Resonance Imaging. Male. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969339.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Halperin EC: Neonatal neoplasms. Int J Radiat Oncol Biol Phys; 2000 Apr 1;47(1):171-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To describe neoplasms diagnosed in children </= 28 days of age along with their treatment, associated congenital anomalies, and the long-term consequences of the diagnoses and treatments.
  • The 20 patients identified via the computerized registry system for 1980-1998 constitute 2% (20/925) of all neoplasms seen in patients </= 16 years of age over this same time period at DUMC.
  • The histologic diagnoses were teratoma/germ cell tumor (n = 8, 35%), neuroblastoma (n = 5, 22%), retinoblastoma (n = 4, 17%), primary central nervous system (CNS) tumor (n = 3, 13%), and one case each of rhabdomyosarcoma, glossal glial choristoma, and hemangioma in the setting of Kasabach-Merritt Syndrome.
  • The one patient with malignant germ cell tumor, treated with surgery and chemotherapy, died.
  • Two were treated with surgery + chemotherapy + radiotherapy; two with surgery + chemotherapy; and one with surgery alone.
  • A child with a dumbbell neuroblastoma, treated with surgery and chemotherapy, is paraplegic.
  • The two children with trilateral retinoblastoma died after therapy with surgery, craniospinal and orbital irradiation, and chemotherapy.
  • Two children with bilateral disease are long-term survivors: one treated with radiotherapy + chemotherapy and one with radiotherapy alone.
  • The three patients with CNS tumors were female.
  • Two of the patients are long-term survivors after surgery + chemotherapy.
  • Six children received eight courses of radiation therapy: 2 for Stage 4S neuroblastoma with respiratory compromise from an enlarging liver and 4 for retinoblastoma.
  • The two infants with trilateral retinoblastoma received two courses of irradiation each: one of the treatment of intraocular tumor and a second, at an older age, for the pineal tumor.
  • The most serious complication of anesthesia was a case of enterobacter cloacae sepsis in the central venous access line used for repetitively administering the anesthetic.
  • Radiation therapy is administered infrequently in a population highly susceptible to late ill effects.
  • When radiotherapy is required, anesthesia may be repetitively administered to aid in reproducible treatment.
  • [MeSH-minor] Anesthesia. Brain Neoplasms / epidemiology. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Female. Follow-Up Studies. Hemangioma / epidemiology. Hemangioma / pathology. Hemangioma / therapy. Humans. Infant, Newborn. Male. Neuroblastoma / epidemiology. Neuroblastoma / pathology. Neuroblastoma / therapy. Registries. Retinoblastoma / epidemiology. Retinoblastoma / pathology. Retinoblastoma / therapy. Survivors. Teratoma / epidemiology. Teratoma / pathology. Teratoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10758320.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


14. Baumgartner JE, Ater JL, Ha CS, Kuttesch JF, Leeds NE, Fuller GN, Wilson RJ: Pathologically proven cavernous angiomas of the brain following radiation therapy for pediatric brain tumors. Pediatr Neurosurg; 2003 Oct;39(4):201-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologically proven cavernous angiomas of the brain following radiation therapy for pediatric brain tumors.
  • Lesions consistent with cavernous angiomas (CAs) of the brain are sometimes seen on MRI scans of the brains of patients who received radiation therapy for brain tumors as children.
  • The lesions appear years later within brain tissue that was included in radiation fields.
  • From 1995 to 1997, 3 patients previously treated with radiation therapy (45-55 Gy) for pediatric brain tumors (medulloblastoma, ependymoma, and a presumed midbrain astrocytoma) underwent resections of symptomatic and enlarging lesions that were consistent with a CA of the brain.
  • None of the patients had received chemotherapy as part of their cancer treatment.
  • The lesions appeared 7-19 years after radiation therapy and slowly enlarged on subsequent imaging studies.
  • The age at resection ranged from 15 to 23 years (10-21 years after radiation therapy).
  • Some CAs may be caused by radiation therapy for pediatric brain tumors.
  • They are radiologically and pathologically similar to sporadically occurring CAs of the brain and may enlarge over time and become symptomatic.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / etiology. Brain Neoplasms / pathology. Ependymoma / radiotherapy. Hemangioma, Cavernous, Central Nervous System / etiology. Hemangioma, Cavernous, Central Nervous System / pathology. Magnetic Resonance Imaging. Medulloblastoma / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / pathology. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Radiography. Time Factors


15. Battaglia F, Uro-Coste E, Delisle MB, Tannier C: [Radiation-induced cavernoma: two cases]. Rev Neurol (Paris); 2008 May;164(5):468-71
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only a few cases of cavernomas induced by radiation treatment, 78 patients, have been reported in the literature.
  • We report new cases of cavernomas induced by radiation treatment.
  • The first case was a 55-year-old man given radiation and chemotherapy for frontal astrocytoma at the age of 46.
  • [MeSH-major] Hemangioma, Cavernous, Central Nervous System / etiology. Hemangioma, Cavernous, Central Nervous System / pathology. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555880.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Paolini S, Morace R, Di Gennaro G, Picardi A, Grammaldo LG, Meldolesi GN, Quarato PP, Raco A, Esposito V: Drug-resistant temporal lobe epilepsy due to cavernous malformations. Neurosurg Focus; 2006;21(1):e8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-resistant temporal lobe epilepsy due to cavernous malformations.
  • OBJECT: Supratentorial cavernous angiomas may be associated with drug-resistant focal epilepsy.
  • In this paper the authors focus on the preoperative workup and the surgical management of the disease in eight consecutive patients undergoing surgery for drug-resistant temporal lobe epilepsy (TLE) due to cavernous malformations (CMs), and the relevant literature on this issue is also reviewed.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / surgery. Epilepsy, Temporal Lobe / etiology. Epilepsy, Temporal Lobe / therapy. Hemangioma, Cavernous, Central Nervous System / complications. Hemangioma, Cavernous, Central Nervous System / surgery
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Drug Resistance / physiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neurosurgical Procedures / methods. Neurosurgical Procedures / trends. Patient Care Team / standards. Patient Care Team / trends. Temporal Lobe / blood supply. Temporal Lobe / pathology. Temporal Lobe / physiopathology. Temporal Lobe / surgery. Treatment Outcome. Vascular Surgical Procedures / methods. Vascular Surgical Procedures / trends

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16859261.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


17. Engelhardt K, Brenneis C, Pfausler B, Beer R, Brössner G, Helbok R, Lackner P, Schmutzhard E: rFVIIa--for acute rebleeding of a cerebral cavernous malformation. Eur J Neurol; 2007 Jan;14(1):117-20
MedlinePlus Health Information. consumer health - Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore brainstem cavernomas are still a therapeutic dilemma and a treatment challenge for the neuro critical care community.
  • A cerebral computed tomography (cCT) revealed a re-bleeding cavernoma in the left cerebral peduncle with consecutive obstructive hydrocephalus.
  • As an off-label treatment, recombinant activated factor VII (rFVIIa) was administered to prevent possible further bleeding and especially further sequelae.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Factor VII / therapeutic use. Hemangioma, Cavernous, Central Nervous System / drug therapy. Hemorrhage / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Factor VIIa. Female. Humans. Recombinant Proteins / therapeutic use

  • Genetic Alliance. consumer health - Cerebral Cavernous Malformation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222126.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / recombinant FVIIa; 9001-25-6 / Factor VII; EC 3.4.21.21 / Factor VIIa
  •  go-up   go-down


18. Belousova OB, Filatov IuM, Shishkina LV, Sazonova OB: [Supratentorial cavernomas: clinical picture, diagnosis, treatment]. Zh Vopr Neirokhir Im N N Burdenko; 2003 Jan-Mar;(1):2-6; discussion 6-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Supratentorial cavernomas: clinical picture, diagnosis, treatment].
  • Different types of their clinical course are analyzed and the optimum diagnostic criteria of the diseases substantiated.
  • In these cases, the indication for surgery may be severe rehemorrhage or drug-untreated frequent seizures.
  • [MeSH-major] Hemangioma, Cavernous, Central Nervous System / diagnosis. Hemangioma, Cavernous, Central Nervous System / therapy. Neurosurgical Procedures. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Anticonvulsants / therapeutic use. Female. Humans. Intracranial Hemorrhages / etiology. Intracranial Hemorrhages / therapy. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Seizures / etiology. Seizures / therapy. Terminology as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12710256.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


19. Ho V, Krol A, Bhargava R, Osiovich H: Diffuse neonatal haemangiomatosis. J Paediatr Child Health; 2000 Jun;36(3):286-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Hemangioma / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Central Nervous System Venous Angioma / diagnosis. Central Nervous System Venous Angioma / drug therapy. Drug Therapy, Combination. Fatal Outcome. Female. Humans. Infant, Newborn. Interferon-alpha / administration & dosage. Magnetic Resonance Imaging. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10849236.001).
  • [ISSN] 1034-4810
  • [Journal-full-title] Journal of paediatrics and child health
  • [ISO-abbreviation] J Paediatr Child Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


20. Pozzati E, Zucchelli M, Marliani AF, Riccioli LA: Bleeding of a familial cerebral cavernous malformation after prophylactic anticoagulation therapy. Case report. Neurosurg Focus; 2006;21(1):e15
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleeding of a familial cerebral cavernous malformation after prophylactic anticoagulation therapy. Case report.
  • Anticoagulation therapy is a well-known risk factor for intracerebral bleeding, but the occurrence of hemorrhages in patients with CMs has not been reported.
  • Low molecular weight heparin therapy is generally considered to be safe, although significant hemorrhagic complications have recently been reported.
  • The authors report a case of intralesional bleeding in a CM after prophylactic anticoagulation therapy was administered in a patient with the familial form of the disease.
  • [MeSH-major] Brain Neoplasms / complications. Cerebral Hemorrhage / chemically induced. Cerebral Veins / drug effects. Hemangioma, Cavernous, Central Nervous System / complications. Heparin, Low-Molecular-Weight / adverse effects
  • [MeSH-minor] Adult. Anticoagulants / adverse effects. Cerebral Cortex / blood supply. Cerebral Cortex / pathology. Cerebral Cortex / physiopathology. Endothelium, Vascular / drug effects. Endothelium, Vascular / physiopathology. Female. Genetic Predisposition to Disease / genetics. Humans. Hysterectomy. Leiomyoma / surgery. Magnetic Resonance Imaging. Microtubule-Associated Proteins / genetics. Mutation / genetics. Postoperative Care. Proto-Oncogene Proteins / genetics. Risk Factors. Thrombosis / drug therapy. Thrombosis / prevention & control

  • Genetic Alliance. consumer health - Cerebral Cavernous Malformation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16859253.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Heparin, Low-Molecular-Weight; 0 / KRIT1 protein, human; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


21. Iakovlev GIu, Devo B, Dreval ON, Advenye E, Nataf F, Befon F, Gossub M, Brami F, Tyurak B, Kuznetsov AV: [Cerebral cavernomas followed by epileptic seizures: clinical picture, diagnosis, and treatment]. Zh Vopr Neirokhir Im N N Burdenko; 2004 Apr-Jun;(2):2-9; discussion 9
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebral cavernomas followed by epileptic seizures: clinical picture, diagnosis, and treatment].
  • The clinical features of epilepsy associated with cerebral cavernomas and the results of different types of its surgical treatment: cavernonectomy, extended cavernomectomy, and epileptic focus resection were analyzed.
  • 1) 21 patients with single and rare seizures and 2) 27 patients with drug-resistant epilepsy.
  • All the patients received medical antiepileptic therapy.
  • In Group 2, 23 patients were operated on and 3 types of operations (cavernomectomy, "extended" cavernomectomy, and corticoectomy) were performed.
  • Criteria associated with the development of drug-resistant epilepsy were established.
  • The paper shows it necessary to choose a surgical intervention in relation to the duration of seizures, their frequency, and a response to medical antiepileptic therapy.
  • The advantages of surgical treatment over medical one were not found in single and rare seizures (Group 1), while in drug-resistant epilepsy, surgical treatment yielded much better epileptological results than did medical treatment.
  • [MeSH-major] Brain Neoplasms / surgery. Epilepsy / surgery. Hemangioma, Cavernous, Central Nervous System / surgery
  • [MeSH-minor] Adult. Anticonvulsants / administration & dosage. Anticonvulsants / therapeutic use. Cerebral Angiography. Electroencephalography. Female. Humans. Magnetic Resonance Imaging. Male. Neuronavigation. Supratentorial Neoplasms / complications. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15326759.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


22. Moschovi M, Alexiou GA, Stefanaki K, Tourkantoni N, Prodromou N: Propranolol treatment for a giant infantile brain cavernoma. J Child Neurol; 2010 May;25(5):653-5
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Propranolol treatment for a giant infantile brain cavernoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Hemangioma, Cavernous, Central Nervous System / drug therapy. Propranolol / therapeutic use
  • [MeSH-minor] Antigens, CD34 / metabolism. Blood Vessels / metabolism. Blood Vessels / pathology. Brain / drug effects. Brain / metabolism. Brain / pathology. Humans. Infant. Iron / metabolism. Magnetic Resonance Imaging. Male. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20413807.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 9Y8NXQ24VQ / Propranolol; E1UOL152H7 / Iron
  •  go-up   go-down


23. Henninger N, Ahmad N, Morris JG: Intravenous thrombolysis in a patient with known cavernous malformation: a first case report. Am J Emerg Med; 2010 Jan;28(1):117.e1-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Central Nervous System Neoplasms / complications. Fibrinolytic Agents / therapeutic use. Hemangioma, Cavernous, Central Nervous System / complications. Stroke / drug therapy. Tissue Plasminogen Activator / therapeutic use
  • [MeSH-minor] Aged. Humans. Male. Thrombolytic Therapy

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20006229.001).
  • [ISSN] 1532-8171
  • [Journal-full-title] The American journal of emergency medicine
  • [ISO-abbreviation] Am J Emerg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


24. Marchione P, Vento C, Marianetti M, Romeo T, Amabile GA, Giacomini P: Hemiballismus in subthalamic haemorrhage: efficacy of levetiracetam. Eur J Neurol; 2009 Jun;16(6):e112-3
Hazardous Substances Data Bank. PIRACETAM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Anticonvulsants / administration & dosage. Dyskinesias / drug therapy. Dyskinesias / pathology. Intracranial Hemorrhage, Hypertensive / complications. Piracetam / analogs & derivatives. Subthalamic Nucleus / pathology
  • [MeSH-minor] Aged. Anti-Dyskinesia Agents / therapeutic use. Antihypertensive Agents / therapeutic use. Ataxia / etiology. Cerebellum / pathology. Cerebellum / physiopathology. Dose-Response Relationship, Drug. Drug Administration Schedule. Haloperidol / therapeutic use. Hemangioma, Cavernous, Central Nervous System / complications. Hemangioma, Cavernous, Central Nervous System / pathology. Humans. Hypertension / complications. Hypertension / drug therapy. Lorazepam / therapeutic use. Magnetic Resonance Imaging. Male. Recurrence. Treatment Outcome. Vomiting / etiology

  • Hazardous Substances Data Bank. HALOPERIDOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453693.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Dyskinesia Agents; 0 / Anticonvulsants; 0 / Antihypertensive Agents; 230447L0GL / etiracetam; J6292F8L3D / Haloperidol; O26FZP769L / Lorazepam; ZH516LNZ10 / Piracetam
  •  go-up   go-down






Advertisement